This study evaluated the efficacy and toxicity of combination chemotherapy with paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin (POFL) in patients with recurrent or metastatic gastric cancer.
One hundred and thirty-eight patients with histologically confirmed recurrent or metastatic gastric adenocarcinoma were treated with the POFL regimen: paclitaxel at a dose of 135 mg/m2 as a 3-hour intravenous infusion on day 1, oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 as an intravenous infusion over 2 hours on day 1, followed by 5-fluorouracil 2,400 mg/m2 as an infusion over a 46-hour period on 3 consecutive days, in a 2-week cycle.
Twelve patients could not be evaluated for response because of the absence of any measurable lesions or early discontinuation of therapy, so responses were assessed in 126 patients. The overall objective response rate was 56.3% (95% CI, 47.5%-64.9%). The median time to progression was 6.7 months (95% CI, 5.8-7.6 months), and the median overall survival was 12.6 months (95% CI, 11.3-13.9 months). The most common grade 3 and 4 toxicities were neutropenia (50.7%), peripheral neurotoxicity (16.7%) and alopecia (27.5%).
Combination chemotherapy with POFL offers a new, active and safe approach to the treatment of recurrent or metastatic gastric cancer.
Post author correction
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsYan-qin Lan, Ri-ping Wu, Xiao-bing Huang, Xin-li Wang, Dong-ta Zhong, Chuan-yong Huang, Jin-tian Song
- • Accepted on 12/06/2017
- • Available online on 27/07/2017
This article is available as full text PDF.
- Lan, Yan-qin [PubMed] [Google Scholar] 1, 2, 3
- Wu, Ri-ping [PubMed] [Google Scholar] 1, 2, 3
- Huang, Xiao-bing [PubMed] [Google Scholar] 1, 2, 3
- Wang, Xin-li [PubMed] [Google Scholar] 1, 2, 3
- Zhong, Dong-ta [PubMed] [Google Scholar] 1, 2, 3, * Corresponding Author (email@example.com)
- Huang, Chuan-yong [PubMed] [Google Scholar] 4
- Song, Jin-tian [PubMed] [Google Scholar] 5
Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian - P.R. China
Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian - P.R. China
Fujian Medical University Stem Cell Research Institute, Fuzhou, Fujian - P.R. China
Department of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, Fujian - P.R. China
Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian - P.R. China
Yan-qin Lan and Chuan-yong Huang contributed equally to this work.